Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its Q3 2025 consolidated provisional financial results, reporting revenue of KRW 1,660.2B (+39.86% YoY), operating profit of KRW 728.8B (+115.27% YoY), and net profit of KRW 574.5B (+117.21% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Performance Period: Q3 2025 (July 1, 2025 – September 30, 2025)
- Q3 2025 Quarterly Results (KRW Million, YoY Change):
- Revenue: KRW 1,660,221M (+28.71% QoQ / +39.86% YoY)
- Operating Profit: KRW 728,848M (+53.25% QoQ / +115.27% YoY)
- Profit Before Income Tax: KRW 767,004M (+87.58% QoQ / +163.58% YoY)
- Net Profit: KRW 574,460M (+77.09% QoQ / +117.21% YoY)
- Net Profit Attributable to Controlling Interests: KRW 574,460M (+77.09% QoQ / +117.21% YoY)
- Q3 2025 Cumulative Results (KRW Million, Cumulative YoY Change):
- Cumulative Revenue: KRW 4,248,399M (+29.10% YoY)
- Cumulative Operating Profit: KRW 1,691,137M (+70.07% YoY)
- Cumulative Profit Before Income Tax: KRW 1,675,295M (+68.20% YoY)
- Cumulative Net Profit: KRW 1,274,399M (+67.28% YoY)
- Cumulative Net Profit Attributable to Controlling Interests: KRW 1,274,399M (+67.28% YoY)
- Information Provision Details:
- Date & Time: October 28, 2025 at 4:30 PM KST
- Target Audience: Domestic and international investors, media, etc.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Final Audit Results and Detailed Quarterly Report Following Provisional Earnings Announcement
This disclosure provides notice of Samsung Biologics’ provisional Q3 2025 operating results prior to the completion of external audit procedures.
Following the reported increases in revenue and operating profit, checking the finalized figures and detailed financial statements in the upcoming quarterly report is essential.
Relevant details can be verified in the subsequent Q3 2025 quarterly report filing and IR materials published on the company’s official website.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
